Treatment of idiopathic membranous nephropathy

Journal of the American Society of Nephrology

Volumn 23, Issue 10, 2012, Pages 1617-1630

  Waldman, Meryl ^a   Austin III, Howard A ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CHLORAMBUCIL; CORTICOTROPIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; TACROLIMUS; TETRACOSACTIDE;

COMORBIDITY; CORTICOSTEROID THERAPY; CREATININE CLEARANCE; DEMYELINATING DISEASE; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; FOLLOW UP; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; LOW DRUG DOSE; MEMBRANOUS GLOMERULONEPHRITIS; MONOTHERAPY; PATHOGENESIS; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEINURIA; REMISSION; REVIEW; SINGLE DRUG DOSE; TREATMENT INDICATION;

EID: 84867182084     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2012010058     Document Type: Review

References (89)

1. Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, Klein JB, Salant DJ: M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 361: 11-21, 2009
2. Heymann W, Hackel DB, Harwood S, Wilson SG, Hunter JL: Production of nephrotic syndrome in rats by Freund's adjuvants and rat kidney suspensions. Proc Soc Exp Biol Med 100: 660-664, 1959
3. Kerjaschki D, Farquhar MG: The pathogenic antigen of Heymann nephritis is a membrane glycoprotein of the renal proximal tubule brush border. Proc Natl Acad Sci USA 79: 5557-5561, 1982 (Pubitemid 13197683)
4. Kerjaschki D, Miettinen A, Farquhar MG: Initial events in the formation of immune deposits in passive Heymann nephritis.gp330-anti-gp330 immune complexes form in epithelial coated pits and rapidly become attached to the glomerular basement membrane. J Exp Med 166: 109-128, 1987 (Pubitemid 17101893)
5. Adler S, Salant DJ, Dittmer JE, Rennke HG, Madaio MP, Couser WG: Mediation of proteinuria in membranous nephropathy due to a planted glomerular antigen. Kidney Int 23: 807-815, 1983 (Pubitemid 13067047)
6. Saito A, Pietromonaco S, Loo AK, Farquhar MG: Complete cloning and sequencing of rat gp330/"megalin," a distinctive member of the low density lipoprotein receptor gene family. Proc Natl Acad Sci USA 91: 9725-9729, 1994
7. Van Damme BJ, Fleuren GJ, Bakker WW, Vernier RL, Hoedemaeker PJ: Experimental glomerulonephritis in the rat induced by antibodies directed against tubular antigens. V. Fixed glomerular antigens in the pathogenesis of heterologous immune complex glomerulonephritis. Lab Invest 38: 502-510, 1978 (Pubitemid 8338244)
8. Couser WG, Steinmuller DR, Stilmant MM, Salant DJ, Lowenstein LM: Experimental glomerulonephritis in the isolated perfused rat kidney. J Clin Invest 62: 1275-1287, 1978 (Pubitemid 9075757)
9. Kerjaschki D, Ullrich R, Diem K, Pietromonaco S, Orlando RA, Farquhar MG: Identification of a pathogenic epitope involved in initiation of Heymann nephritis. Proc Natl Acad Sci USA 89: 11179-11183, 1992
10. Beck LH Jr, Salant DJ: Membranous nephropathy: Recent travels and new roads ahead. Kidney Int 77: 765-770, 2010
11. 2-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol Dial Transplant 26: 2526-2532, 2011
12. 2 receptor antibody inmembranous nephropathy. J Am Soc Nephrol 22: 1137-1143, 2011
13. 2 receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 6: 1286-1291, 2011
14. Beck LH Jr, Fervenza FC, Beck DM, Bonegio RG, Malik FA, Erickson SB, Cosio FG, Cattran DC, Salant DJ: Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 22: 1543-1550, 2011
15. Murtas C, Ravani P, Ghiggeri GM: New insights into membranous glomerulonephritis: From bench to bedside. Nephrol Dial Transplant 26: 2428-2430, 2011
16. Prunotto M, Carnevali ML, Candiano G, Murtas C, Bruschi M, Corradini E, Trivelli A, Magnasco A, Petretto A, Santucci L, Mattei S, Gatti R, Scolari F, Kador P, Allegri L, Ghiggeri GM: Autoimmunity in membranous nephropathy targets aldose reductase and SOD2. J Am Soc Nephrol 21: 507-519, 2010
17. Bruschi M, Carnevali ML, Murtas C, Candiano G, Petretto A, Prunotto M, Gatti R, Argentiero L, Magistroni R, Garibotto G, Scolari F, Ravani P, Gesualdo L, Allegri L, Ghiggeri GM: Direct characterization of target podocyte antigens and auto-antibodies in human membranous glomerulonephritis: Alfa-enolase and borderline antigens. J Proteomics 74: 2008-2017, 2011
18. Ronco P, Debiec H: Antigen identification in membranous nephropathy moves toward targeted monitoring and new therapy. J Am Soc Nephrol 21: 564-569, 2010
19. Couser WG: Basic and translational concepts of immune-mediated glomerular diseases. J Am Soc Nephrol 23: 381-399, 2012
20. Stanescu HC, Arcos-Burgos M, Medlar A, Bockenhauer D, Kottgen A, Dragomirescu L, Voinescu C, Patel N, Pearce K, Hubank M, Stephens HA, Laundy V, Padmanabhan S, Zawadzka A, Hofstra JM, Coenen MJ, den Heijer M, Kiemeney LA, Bacq-Daian D, Stengel B, Powis SH, Brenchley P, Feehally J, Rees AJ, Debiec H, Wetzels JF, Ronco P, Mathieson PW, Kleta R: Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. N Engl J Med 364: 616-626, 2011
21. Polanco N, Gutiérrez E, Covarsí A, Ariza F, Carreño A, Vigil A, Baltar J, Fernández-Fresnedo G, Martín C, Pons S, Lorenzo D, Bernis C, Arrizabalaga P, Fernández-Juárez G, Barrio V, Sierra M, Castellanos I, Espinosa M, Rivera F, Oliet A, Fernández-Vega F, Praga M; Grupo de Estudio de las Enfermedades Glomerulares de la Sociedad Española de Nefrología: Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol 21: 697-704, 2010
22. McQuarrie EP, Stirling CM, Geddes CC: Idiopathic membranous nephropathy and nephrotic syndrome: outcome in the era of evidence-based therapy [published online ahead of print May 10, 2011]. Nephrol Dial Transplant doi:10.1093/ndt/gfr220
23. Noel LH, Zanetti M, Droz D, Barbanel C: Long-term prognosis of idiopathic membranous glomerulonephritis. Study of 116 untreated patients. Am J Med 66: 82-90, 1979 (Pubitemid 9089829)
24. Donadio JV Jr, Torres VE, Velosa JA, Wagoner RD, Holley KE, Okamura M, Ilstrup DM, Chu CP: Idiopathic membranous nephropathy: The natural history of untreated patients. Kidney Int 33: 708-715, 1988 (Pubitemid 18083120)
25. Schieppati A, Mosconi L, Perna A, Mecca G, Bertani T, Garattini S, Remuzzi G: Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med 329: 85-89, 1993 (Pubitemid 23188821)
26. Davison AM, Cameron JS, Kerr DN, Ogg CS, Wilkinson RW: The natural history of renal function in untreated idiopathic membranous glomerulonephritis in adults. Clin Nephrol 22: 61-67, 1984 (Pubitemid 14054423)
27. Hladunewich MA, Troyanov S, Calafati J, Cattran DC; Metropolitan Toronto Glomerulonephritis Registry: The natural history of the non-nephrotic membranous nephropathy patient. Clin J Am Soc Nephrol 4: 1417-1422, 2009
28. Cattran D: Management of membranous nephropathy: When and what for treatment. J Am Soc Nephrol 16: 1188-1194, 2005
29. Polanco N, Gutierrez E, Rivera F, Castellanos I, Baltar J, Lorenzo D, Praga M: Spontaneous remission of nephrotic syndrome in membranous nephropathy with chronic renal impairment. Nephrol Dial Transplant 27: 231-234, 2012
30. Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC; Toronto Glomerulonephritis Registry Group: Idiopathic membranous nephropathy: Definition and relevance of a partial remission. Kidney Int 66: 1199-1205, 2004 (Pubitemid 39121029)
31. Fervenza FC, Sethi S, Specks U: Idiopathic membranous nephropathy: Diagnosis and treatment. Clin J Am Soc Nephrol 3: 905-919, 2008
32. Praga M, Hernández E, Montoyo C, Andrés A, Ruilope LM, Rodicio JL: Long-term beneficial effects of angiotensin-converting enzyme inhibition in patients with nephrotic proteinuria. Am J Kidney Dis 20: 240-248, 1992
33. Rostoker G, Ben Maadi A, Remy P, Lang P, Lagrue G, Weil B: Low-dose angiotensin-converting-enzyme inhibitor captopril to reduce proteinuria in adult idiopathic membranous nephropathy: A prospective study of long-term treatment. Nephrol Dial Transplant 10: 25-29, 1995
34. du Buf-Vereijken PW, Branten AJ, Wetzels JF;Membranous Nephropathy Study Group: Cytotoxic therapy for membranous nephropathy and renal insuf ficiency: Improved renal survival but high relapse rate. Nephrol Dial Transplant 19: 1142-1148, 2004
35. du Buf-Vereijken PW, Branten AJ, Wetzels JF: Idiopathic membranous nephropathy: Outline and rationale of a treatment strategy. Am J Kidney Dis 46: 1012-1029, 2005
36. Ruggenenti P, Mosconi L, Vendramin G, Moriggi M, Remuzzi A, Sangalli F, Remuzzi G: ACE inhibition improves glomerular size selectivity in patients with idiopathic membranous nephropathy and persistent nephrotic syndrome. Am J Kidney Dis 35: 381-391, 2000
37. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, Maschio G, Brenner BM, Kamper A, Zucchelli P, Becker G, Himmelmann A, Bannister K, Landais P, Shahinfar S, de Jong PE, de Zeeuw D, Lau J, Levey AS: Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 135: 73-87, 2001 (Pubitemid 32661190)
38. Ruggenenti P: Angiotensin-converting enzyme inhibition and angiotensin II antagonism in nondiabetic chronic nephropathies. Semin Nephrol 24: 158-167, 2004
39. Ponticelli C, Zucchelli P, Passerini P, Cagnoli L, Cesana B, Pozzi C, Pasquali S, Imbasciati E, Grassi C, Redaelli B, Sasdelli M, Locatelli F: A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 320: 8-13, 1989 (Pubitemid 19033056)
40. Ponticelli C, Zucchelli P, Passerini P, Cesana B, Locatelli F, Pasquali S, Sasdelli M, Redaelli B, Grassi C, Pozzi C, Bizzarri D, Banfi G: A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int 48: 1600-1604, 1995
41. Jha V, Ganguli A, Saha TK, Kohli HS, Sud K, Gupta KL, Joshi K, Sakhuja V: A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol 18: 1899-1904, 2007 (Pubitemid 46870326)
42. Hofstra JM, Branten AJ, Wirtz JJ, Noordzij TC, du Buf-Vereijken PW, Wetzels JF: Early versus late start of immunosuppressive therapy in idiopathic membranous nephropathy: A randomized controlled trial. Nephrol Dial Transplant 25: 129-136, 2010
43. Ponticelli C, Altieri P, Scolari F, Passerini P, Roccatello D, Cesana B, Melis P, Valzorio B, Sasdelli M, Pasquali S, Pozzi C, Piccoli G, Lupo A, Segagni S, Antonucci F, Dugo M, Minari M, Scalia A, Pedrini L, Pisano G, Grassi C, Farina M, Bellazzi R: A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol 9: 444-450, 1998 (Pubitemid 28122870)
44. du Buf-Vereijken PW, Feith GW, Hollander D, Gerlag PG, Wirtz JJ, Noordzij TC, Wetzels JF; Membranous Nephropathy Study Group: Restrictive use of immunosuppressive treatment in patients with idiopathic membranous nephropathy: High renal survival in a large patient cohort. QJM 97: 353-360, 2004
45. Knight A, Askling J, Granath F, Sparen P, Ekbom A: Urinary bladder cancer in Wegener's granulomatosis: Risks and relation to cyclophosphamide. Ann Rheum Dis 63: 1307-1311, 2004 (Pubitemid 39273514)
46. Westman KW, Bygren PG, Olsson H, Ranstam J, Wieslander J: Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol 9: 842-852, 1998 (Pubitemid 28209094)
47. Faurschou M, Sorensen IJ, Mellemkjaer L, Loft AG, Thomsen BS, Tvede N, Baslund B: Malignancies in Wegener's granulomatosis: Incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 35: 100-105, 2008
48. Cattran DC, Alexopoulos E, Heering P, Hoyer PF, Johnston A, Meyrier A, Ponticelli C, Saito T, Choukroun G, Nachman P, Praga M, Yoshikawa N: Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome: Workshop recommendations. Kidney Int 72: 1429-1447, 2007 (Pubitemid 350197945)
49. Praga M, Barrio V, Juárez GF, Luño J; Grupo Español de Estudio de la Nefropatía Membranosa: Tacrolimus monotherapy in membranous nephropathy: A randomized controlled trial. Kidney Int 71: 924-930, 2007 (Pubitemid 46663803)
50. Chen M, Li H, Li XY, Lu FM, Ni ZH, Xu FF, Li XW, Chen JH, Wang HY; Chinese Nephropathy Membranous Study Group: Tacrolimus combined with corticosteroids in treatment of nephrotic idiopathic membranous nephropathy: A multicenter randomized controlled trial. Am J Med Sci 339: 233-238, 2010
51. Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, Maxwell DR, Kunis CL; North America Nephrotic Syndrome Study Group: Cyclosporine in patients with steroid-resistant membranous nephropathy: A randomized trial. Kidney Int 59: 1484-1490, 2001 (Pubitemid 32281239)
52. Naumovic R, Jovanovic D, Pavlovic S, Stosovic M, Marinkovic J, Basta-Jovanovic G: Cyclosporine versus azathioprine therapy in high-risk idiopathic membranous nephropathy patients: A 3-year prospective study. Biomed Pharmacother 65: 105-110, 2011
53. Fritsche L, Budde K, Färber L, Charissé G, Kunz R, Gaedeke J, Neumayer HH: Treatment of membranous glomerulopathy with cyclosporin A: How much patience is required? Nephrol Dial Transplant 14: 1036-1038, 1999 (Pubitemid 29155183)
54. DeSanto NG, Capodicasa G, Giordano C: Treatment of idiopathic membranous nephropathy unresponsive to methylprednisolone and chlorambucil with cyclosporin. Am J Nephrol 7: 74-76, 1987 (Pubitemid 17037532)
55. Alexopoulos E, Papagianni A, Tsamelashvili M, Leontsini M, Memmos D: Induction and long-term treatment with cyclosporine in membranous nephropathy with the nephrotic syndrome. Nephrol Dial Transplant 21: 3127-3132, 2006 (Pubitemid 44567084)
56. Cattran DC, Greenwood C, Ritchie S, Bernstein K, Churchill DN, Clark WF, Morrin PA, Lavoie S; Canadian Glomerulonephritis Study Group: A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Kidney Int 47: 1130-1135, 1995
57. Rostoker G, Belghiti D, Ben Maadi A, Rémy P, Lang P, Weil B, Lagrue G: Long-term cyclosporin A therapy for severe idiopathic membranous nephropathy. Nephron 63: 335-341, 1993 (Pubitemid 23082077)
58. Pisoni R, Grinyo JM, Salvadori M, Laurens W, Garini G, Oliver YA, Mezzano S, Ruggenenti P, Remuzzi G: Cyclosporine versus conservative therapy in patients with idiopathic membranous nephropathy and deteriorating renal function: Results of the CYCLOMEN trial [Abstract]. J Am Soc Nephrol 11: 0514A, 2000
59. Goumenos DS, Katopodis KP, Passadakis P, Vardaki E, Liakopoulos V, Dafnis E, Stefanidis I, Vargemezis V, Vlachojannis JG, Siamopoulos KC: Corticosteroids and ciclosporin A in idiopathic membranous nephropathy: Higher remission rates of nephrotic syndrome and less adverse reactions than after traditional treatment with cytotoxic drugs. Am J Nephrol 27: 226-231, 2007 (Pubitemid 47164670)
60. Remuzzi G, Chiurchiu C, Abbate M, Brusegan V, Bontempelli M, Ruggenenti P: Rituximab for idiopathic membranous nephropathy. Lancet 360: 923-924, 2002 (Pubitemid 35283838)
61. Ruggenenti P, Chiurchiu C, Brusegan V, Abbate M, Perna A, Filippi C, Remuzzi G: Rituximab in idiopathic membranous nephropathy: A one-year prospective study. J Am Soc Nephrol 14: 1851-1857, 2003 (Pubitemid 36750480)
62. Ruggenenti P, Chiurchiu C, Abbate M, Perna A, Cravedi P, Bontempelli M, Remuzzi G: Rituximab for idiopathic membranous nephropathy: Who can benefit? Clin J Am Soc Nephrol 1: 738-748, 2006
63. Cravedi P, Ruggenenti P, Sghirlanzoni MC, Remuzzi G: Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2: 932-937, 2007
64. Cravedi P, Sghirlanzoni MC, Marasà M, Salerno A, Remuzzi G, Ruggenenti P: Efficacy and safety of rituximab second-line therapy for membranous nephropathy: A prospective, matched-cohort study. Am J Nephrol 33: 461-468, 2011
65. Fervenza FC, Cosio FG, Erickson SB, Specks U, Herzenberg AM, Dillon JJ, Leung N, Cohen IM, Wochos DN, Bergstralh E, Hladunewich M, Cattran DC: Rituximab treatment of idiopathic membranous nephropathy. Kidney Int 73: 117-125, 2008 (Pubitemid 350273646)
66. Fervenza FC, Abraham RS, Erickson SB, Irazabal MV, Eirin A, Specks U, Nachman PH, Bergstralh EJ, Leung N, Cosio FG, Hogan MC, Dillon JJ, Hickson LJ, Li X, Cattran DC; Mayo Nephrology Collaborative Group: Rituximab therapy in idiopathic membranous nephropathy: A 2-year study. Clin J Am Soc Nephrol 5: 2188-2198, 2010
67. Ruggenenti P, Cravedi P, Sghirlanzoni MC, Gagliardini E, Conti S, Gaspari F, Marchetti G, Abbate M, Remuzzi G: Effects of rituximab on morphofunctional abnormalities of membranous glomerulopathy. Clin J Am Soc Nephrol 3: 1652-1659, 2008
68. Miller G, Zimmerman R 3rd, Radhakrishnan J, Appel G: Use of mycophenolate mofetil in resistant-membranous nephropathy. Am J Kidney Dis 36: 250-256, 2000 (Pubitemid 30485832)
69. Choi MJ, Eustace JA, Gimenez LF, Atta MG, Scheel PJ, Sothinathan R, Briggs WA: Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 61: 1098-1114, 2002 (Pubitemid 34175479)
70. Polenakovic M, Grcevska L, Dzikova S: Mycophenolate mofetil in treatment of idiopathic stages III-IV membranous nephropathy. Nephrol Dial Transplant 18: 1233-1234, 2003 (Pubitemid 36722535)
71. Ballarin J, Poveda R, Ara J, Pérez L, Calero F, Grinyó JM, Romero R: Treatment of idiopathic membranous nephropathy with the combination of steroids, tacrolimus and mycophenolate mofetil: Results of a pilot study. Nephrol Dial Transplant 22: 3196-3201, 2007 (Pubitemid 350202550)
72. Dimkovic N, Jovanovic D, Kovacevic Z, Rabrenovic V, Nesic V, Savin M, Mitic B, Ratkovic M, Curic S, Mitic I, Pljesa S, Perunicic-Pekovic G, Marinkovic J, Popovic J, Vujic D: Mycophenolate mofetil in high-risk patients with primary glomerulonephritis: Results of a 1-year prospective study. Nephron Clin Pract 111: c189-c196, 2009
73. Dussol B, Morange S, Burtey S, Indreies M, Cassuto E, Mourad G, Villar E, Pouteil-Noble C, Karaaslan H, Sichez H, Lasseur C, Delmas Y, Nogier MB, Fathallah M, Loundou A, Mayor V, Berland Y: Mycophenolate mofetil monotherapy in membranous nephropathy: A 1-year randomized controlled trial. Am J Kidney Dis 52: 699-705, 2008
74. Chan TM, Lin AW, Tang SC, Qian JQ, Lam MF, Ho YW, Tse KC, Chan KW, Lai KN, Tang CS: Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome. Nephrology (Carlton) 12: 576-581, 2007 (Pubitemid 350059122)
75. Branten AJ, du Buf-Vereijken PW, Vervloet M, Wetzels JF: Mycophenolate mofetil in idiopathic membranous nephropathy: A clinical trialwith comparison to a historic control group treated with cyclophosphamide. Am J Kidney Dis 50: 248-256, 2007
76. Senthil Nayagam L, Ganguli A, Rathi M, Kohli HS, Gupta KL, Joshi K, Sakhuja V, Jha V: Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: A pilot study. Nephrol Dial Transplant 23: 1926-1930, 2008 (Pubitemid 351768140)
77. Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, Lau CS, Wong AK, Tong MK, Chan KW, Lai KN; Hong Kong-Guangzhou Nephrology Study Group: Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 343: 1156-1162, 2000
78. Rivera TL, Belmont HM, Malani S, Latorre M, Benton L, Weisstuch J, Barisoni L, Tseng CE, Izmirly PM, Buyon JP, Askanase AD: Current therapies for lupus nephritis in an ethnically heterogeneous cohort. J Rheumatol 36: 298-305, 2009
79. Yau WP, Vathsala A, Lou HX, Chan E: Is a standard fixed dose of mycophenolate mofetil ideal for all patients? Nephrol Dial Transplant 22: 3638-3645, 2007 (Pubitemid 350212500)
80. Brown JH, Douglas AF, Murphy BG, Hill CM, McNamee PT, Nelson WE, Doherty CC: Treatment of renal failure in idiopathic membranous nephropathy with azathioprine and prednisolone. Nephrol Dial Transplant 13: 443-448, 1998 (Pubitemid 28062210)
81. Ahuja M, Goumenos D, Shortland JR, Gerakis A, Brown CB: Does immunosuppression with prednisolone and azathioprine alter the progression of idiopathic membranous nephropathy? Am J Kidney Dis 34: 521-529, 1999 (Pubitemid 29413626)
82. Berg AL, Nilsson-Ehle P, Arnadottir M: Beneficial effects of ACTH on the serum lipoprotein profile and glomerular function in patients with membranous nephropathy. Kidney Int 56: 1534-1543, 1999 (Pubitemid 29451260)
83. Rauen T, Michaelis A, Floege J, Mertens PR: Case series of idiopathic membranous nephropathy with long-term bene ficial effects of ACTH peptide 1-24. Clin Nephrol 71: 637-642, 2009
84. Berg AL, Arnadottir M: ACTH-induced improvement in the nephrotic syndrome in patients with a variety of diagnoses. Nephrol Dial Transplant 19: 1305-1307, 2004
85. Picardi L, Villa G, Galli F, Piazza V, Bovio G, Efficace E, Montagna G, Semeraro L, Segagni S, Salvadeo A: ACTH therapy in nephrotic syndrome induced by idiopathic membranous nephropathy. Clin Nephrol 62: 403-404, 2004 (Pubitemid 39480853)
86. Lindskog A, Ebefors K, Johansson ME, Stefánsson B, Granqvist A, Arnadottir M, Berg AL, Nyström J, Haraldsson B: Melanocortin 1 receptor agonists reduce proteinuria. J Am Soc Nephrol 21: 1290-1298, 2010
87. Ponticelli C, Passerini P, Salvadori M, Manno C, Viola BF, Pasquali S, Mandolfo S, Messa P: A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy. Am J Kidney Dis 47: 233-240, 2006 (Pubitemid 43121326)
88. Hofstra J, Brink H, Van de Kerkhof J, Wetzels J: Synthetic ACTH is less effective than cyclophosphamide in patients with idiopathic membranous nephropathy [Abstract]. J Am Soc Nephrol 22: A773, 2011
89. Bomback AS, Radhakrishnan J: Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH). Discov Med 12: 91-96, 2011